Twin Lakes Capital Management’s Alterity Therapeutics ATHE Stock Holding History
Bought
Maintained
Sold
Other funds holding ATHE
HWM
GT
GI
BTI
Twin Lakes Capital Management's ATHE Position: Q1 2026 in Review
Twin Lakes Capital Management held its Alterity Therapeutics (ATHE) position steady in Q1 2026 at 139,258 shares worth $485K. The position accounts for 0.22% of the portfolio, ranked #57.
Twin Lakes Capital Management first reported a position in ATHE in Q1 2023 and has held it in 13 quarters since. The position peaked at $524K in Q3 2025. 15 funds tracked by Wall St. Rank hold ATHE as of Q1 2026.
- Twin Lakes Capital Management held 139,258 shares of Alterity Therapeutics worth $485K as of Q1 2026.
- Twin Lakes Capital Management left its Alterity Therapeutics share count unchanged in Q1 2026.
- Alterity Therapeutics made up 0.22% of Twin Lakes Capital Management's portfolio in Q1 2026, its #57 holding.
- Twin Lakes Capital Management first reported a position in Alterity Therapeutics in Q1 2023 and has held it in 13 quarters since.
- Twin Lakes Capital Management's Alterity Therapeutics position peaked at $524K in Q3 2025.
- 15 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q1 2026.
Based on Twin Lakes Capital Management's 13F filing for Q1 2026, filed 18 May 2026.